{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-038031","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.457965+00:00","generated_at":"2026-05-17T04:02:35.935309+00:00","sec_items":["1.01","2.02","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioCryst to acquire Astria Therapeutics for 0.59 shares + $8.55 cash per share; Q3 ORLADEYO strong","bullets":["Merger: each Astria share → 0.59 BCRX shares + $8.55 cash; expected close Q1 2026.","Blackstone provides $550M senior secured credit facility ($350M term loan + $50M committed delayed draw + $150M uncommitted) to fund deal.","Q3 2025: ORLADEYO demand strong with no impact from new competition (no specific figures given).","Astria CEO Jill Milne appointed to BioCryst board effective at merger close; receives $500K equity grant.","BioCryst paid off and terminated April 2023 loan agreement with BioPharma Credit PLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-038031","json":"https://secwatch.observer/filing/0001140361-25-038031.json","markdown":"https://secwatch.observer/filing/0001140361-25-038031.md","text":"https://secwatch.observer/filing/0001140361-25-038031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/0001140361-25-038031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/ef20057029_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:02:35.935309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}